JAKAFI Reviews (RUXOLITINIB PHOSPHATE)

Average Rating: 2.5 (2 Ratings)

Filter Results

Compare JAKAFI with similar:

 Type: Rx Drug

  

JAKAFI  (RUXOLITINIB PHOSPHATE):  This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as JAK inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain.   FDA Approval Date: 2011-11-16 (Sources: U.S. Centers for Medicare Services, FDA)

  

Results are sorted by Date added.

Key to Ratings: 1=LOW (I would not recommend taking this medicine.)
5=HIGH (this medicine cured me or helped me a great deal.)

Page: 1


RATING  REASONSIDE EFFECTS FOR JAKAFICOMMENTSSEXAGEDURATION/
DOSAGE
DATE ADDED
 
 1  GVHD Weight gain, bruising, eye hematomas No noticeable benefit from Jakarta and I paid over $3000 for 2 months of pills M 74 2 months
10mg 1X day
5/21/2022
Email
 4  Polycythemia vera Dry mouth some dizziness mild weight loss Much easier to tolerate than Hydroxyurea F 64 31 days
5 mg 2X day
11/21/2016
Email
  

JAKAFI  (RUXOLITINIB PHOSPHATE):  This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as JAK inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain.   FDA Approval Date: 2011-11-16 (Sources: U.S. Centers for Medicare Services, FDA)

     

BACK TO TOP